Buy now (speculative biotech) given the still-bullish price structure (SMA_5 > SMA_20 > SMA_200) plus very bullish options positioning (extremely low put/call OI) and a clear upward shift in Wall Street price targets.
Near-term setup favors continuation as long as price holds the 5.80 pivot; upside levels to watch are 6.21 then 6.47.
Biggest counterweight is fundamentals (sharp YoY revenue decline, widening loss) plus notable insider selling; this is a catalyst/trader-driven name, not a fundamentals-driven one.
Technical Analysis
Trend: Bullish moving-average stack (SMA_5 > SMA_20 > SMA_200) signals an established uptrend.
Momentum: MACD histogram is positive (0.0586) but contracting, implying upside momentum is cooling rather than reversing.
RSI (6): 66.71 (neutral-to-warm) suggests the stock is not deeply overbought yet, but it’s leaning stretched.
Key levels: Pivot 5.80 (must-hold); Support S1 5.39 then S2 5.13; Resistance R1 6.21 then R2 6.47.
Tape today: Regular session down (-3.38%) but pre-market up (+2.14%), consistent with dip-buying interest.
Pattern-based outlook: Model implies mild near-term drift (next day -0.45%), but positive bias week/month (+0.86% / +4.88%).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Extremely call-heavy positioning (put/call OI 0.07) = strongly bullish/low-demand for protection.
Activity: Volume elevated vs 30-day average (today vs avg ~17.46x), signaling a live sentiment/positioning shift.
Volatility: IV 30d ~166.77 vs HV ~89.04; IV percentile ~72.91 (options are expensive; market is pricing big moves).
Interpretation: Options market is positioned for upside, but the high IV means the market expects large swings (good for directional traders; costly for late option buyers).
Technical Summary
Sell
2
Buy
8
Positive Catalysts
keep attention on the name.
Neutral/Negative Catalysts
Insiders are selling: Selling amount up +359.35% over the last month (often a near-term sentiment overhang).
No supportive news flow this week: With no fresh headlines, momentum can fade and trade more technically.
Very high implied volatility: Bigger drawdowns are common when IV is elevated and expectations are high.
Market risk: Broad market mildly down (S&P 500 -0.19% today), which can pressure higher-beta biotech names.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: 5.963M, down -82.16% YoY (sharp contraction).
Net income: -14.229M, down -348.06% YoY (loss widened materially).
EPS: -0.09, down -228.57% YoY.
Gross margin: 100 (stable), but overall results indicate the story is primarily pipeline/catalyst-driven rather than current earnings strength.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Trend: Clear upgrading cycle since Nov 2025 into Jan–Feb 2026 with multiple target raises and initiations.
Latest: Barclays raised PT to $10 (from $8) and maintained Overweight (2026-02-04).
Wall Street analysts forecast CTMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTMX is 7.1 USD with a low forecast of 6 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast CTMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTMX is 7.1 USD with a low forecast of 6 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.240
Low
6
Averages
7.1
High
10
Current: 5.240
Low
6
Averages
7.1
High
10
Barclays
Overweight
upgrade
$8 -> $10
AI Analysis
2026-02-04
New
Reason
Barclays
Price Target
$8 -> $10
AI Analysis
2026-02-04
New
upgrade
Overweight
Reason
Barclays raised the firm's price target on CytomX Therapeutics to $10 from $8 and keeps an Overweight rating on the shares as part of a Q4 earnings preview for the biotechnology group.
Barclays
Etzer Darout
Overweight
maintain
$6 -> $8
2026-01-20
Reason
Barclays
Etzer Darout
Price Target
$6 -> $8
2026-01-20
maintain
Overweight
Reason
Barclays analyst Etzer Darout raised the firm's price target on CytomX Therapeutics to $8 from $6 and keeps an Overweight rating on the shares. The firm believes the company's upcoming readout in colorectal cancer has "compelling risk-reward."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CTMX
